|
Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD)
RECRUITINGPhase 4Sponsored by CSL Behring
Actively Recruiting
PhasePhase 4
SponsorCSL Behring
Started2026-09-29
Est. completion2033-09-15
Eligibility
Age18 Years – 65 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07326592
Summary
This is a multicenter, parallel-group, double-blind, randomized phase 4 study designed to identify the optimal dose of CE1226 (2 active doses) to slow disease progression as assessed by reduced rates of annual lung density decline in alpha-1 antitrypsin (AAT) deficient participants over 3 years as compared with the marketed dose 60 milligrams per kilogram (mg/kg).
Eligibility
Age: 18 Years – 65 YearsHealthy volunteers accepted
Inclusion Criteria: * Age greater than or equal to (\>=) 18 and less than or equal to (\<=) 65 years at the time of providing written informed consent. * Confirmed diagnosis of emphysema related to AATD with either the PiZZ, PiZ(null), or Pi(null/null) genotype with documented serum AAT levels less than (\<) 11 micrometer (μM) (or \< 50 mg/dL \[milligram/deciliter\]) at any time before the first administration of CE1226 on Day 1 (Baseline). Exclusion Criteria: * Participants should not have acute illness or pulmonary exacerbation within 6 weeks before the first administration of CE1226 on Day 1 (Baseline). * Participants should not have previously received gene therapy for AATD at any point. * Participants with liver disease secondary to AATD.
Conditions4
Alpha1-Antitrypsin DeficiencyAlpha1-Proteinase Inhibitor DeficiencyEmphysemaLiver Disease
Interventions1
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 4
SponsorCSL Behring
Started2026-09-29
Est. completion2033-09-15
Eligibility
Age18 Years – 65 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07326592